Last reviewed · How we verify
NCT02932501: MRONJ
International, Multicenter, Prospective Registry to Collect Data of Treatment Patterns of Patients With Medication-related Osteonecrosis of the Jaw (MRONJ) and Their Outcome
trial testing Conservative treatment in Medication-related Osteonecrosis of the Jaw in 518 participants. Status unknown.
13 October 2023
Quick facts
| Lead sponsor | AO Clinical Investigation and Publishing Documentation |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 518 |
| Start date | 14 August 2017 |
| Primary completion | 13 October 2023 |
| Estimated completion | 1 April 2024 |
| Sites | 14 locations across United States, Finland, Germany, Netherlands, Qatar, Romania, Slovenia, South Korea |
Drugs / interventions tested
- Conservative treatment — full drug profile →
- Surgical treatment
- Adjuvant non-surgical treatment
Conditions studied
- Medication-related Osteonecrosis of the Jaw — all drugs for Medication-related Osteonecrosis of the Jaw →
- Bisphosphonate-Associated Osteonecrosis of the Jaw — all drugs for Bisphosphonate-Associated Osteonecrosis of the Jaw →
Sponsor
AO Clinical Investigation and Publishing Documentation
Who can join
18 and older, any sex, with Medication-related Osteonecrosis of the Jaw or Bisphosphonate-Associated Osteonecrosis of the Jaw. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Treatment outcome
Time frame: 6 months / 1 year
Compared to the baseline status of the patient's condition, the outcome will be evaluated as: * Worsening of the osteonecrosis (e.g. size of the lesion increased) * No change of the osteonecrosis * Reduction of the osteonecrosis (e.g. size of the lesion decrease) * Complete mucosa healing
Sponsor's own description
Approximately 500 patients will be included in this patient registry. Data collection includes demographics, clinical data of underlying disease and use of bisphosphonates, denosumab and antiangiogenic drugs , degree and extension of osteonecrosis, osteonecrosis-specific treatment, outcomes and complications within 1 year after treatment.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Outcomes of Clinical Trials on Osteonecrosis of the Jaw.
Wu BW, Lee KC, Halepas S, Karlis V. · · 2021 · PMID 34660159 · DOI 10.7759/cureus.17984
Verify or expand the search:
- PubMed search for NCT02932501
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Conservative treatment
Trials testing the same drug.
- NCT07017647 — Comparison of the Effectiveness of Conventional Treatment and Patient Education in Addition to Conventional Treatment in · NA · completed
- NCT06671223 — Effectiveness of Infiltrations in the Treatment of Plantar Fasciopathy · NA · not yet recruiting
- NCT06981715 — Investigation of the Efficacy of Extracorporeal Shock Wave Therapy and Kinesiotaping Applied as an Addition to Conservat · NA · completed
- NCT06602414 — Evaluation of Clinical Results of Patients Treated Conservatively for Distal Biceps Tendon Lesions · completed
- NCT07022132 — Comparison of Physiotherapy Methods Applied To The Diaphragm In Chronic Low Back Pain · NA · completed
Other AO Clinical Investigation and Publishing Documentation trials
Trials by the same sponsor.
- NCT03380273 — AO Multicenter Intervention Trial for Prevention of Surgical Site Infection · NA · terminated
- NCT03849898 — Patients 60 Years and Older Suffering From Mandibular Fractures Registry · terminated
- NCT03598530 — Fracture-Related Outcome Study for Operatively Treated Tibia Shaft Fractures · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02932501 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by AO Clinical Investigation and Publishing Documentation
- Last refreshed: 19 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02932501.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing